Title

Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients
Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Status

    Terminated
  • Intervention/Treatment

    valsartan ...
  • Study Participants

    88
Dual chamber pacing is known to induce left ventricle remodeling and may eventually lead to heart failure. The investigators aim to test hypothesis that valsartan started immediately after dual chamber pacemaker implantation will prevent left ventricle remodeling in twelve months long follow up in comparison with placebo. Echocardiographic assessment of left ventricle remodeling will be correlated with plasma activity of matrix metalloproteinases and their tissue inhibitors, indices of functional capacity such as plasma level of NTproBNP and distance in meters during six minute walking test.
Study Started
Jan 31
2017
Primary Completion
Jan 31
2019
Study Completion
Jan 31
2019
Last Update
Apr 12
2023

Drug placebo/valsartan

  • Other names: Valsartan, Other names:, Diovan, Axudan, Vanatex

Placebo Placebo Comparator

Placebo pills to match valsartan tablets administered once daily

valsartan 80mg daily Experimental

Valsartan 80mg tablet once daily

valsartan 160mg daily Experimental

Valsartan 160mg tablet once daily

Criteria

Inclusion Criteria:

informed written consent
age ≥ 18 years
first time pacemaker implantation for trifascicular block, atrioventricular second or third degree block
left ventricle ejection fraction ≥ 40%

Exclusion Criteria:

significant valvular heart disease
ischaemic heart disease requiring further revascularization
symptomatic hypotension
orthostatic disorders
pregnancy, breast feeding, child bearing potential
previous use of angiotensin receptor blocking agents
known hypersensitivity to valsartan
significant liver disorders
significant renal disorders, including renal artery stenosis
hyperaldosteronism
chronic use of nonsteroid antiinflammatory drugs
chronic use of lithium salts
Patient's reluctance or disability to obey protocol and/or follow the scheduled visits
any significant disease to reduce the expected life duration < 12 months
participation in any other trial within the last 30 days before randomization
any situation that would put more risk on patient
No Results Posted